Judge Rejects Teva’s Suit to Fight US Drug Price Negotiations

Teva Pharmaceuticals Inc.’s claims against a Biden-era drug price negotiation program either fail on the merits or are unripe, a federal judge ruled Thursday.

Judge Sparkle L. Sooknanan ruled the company couldn’t prove that the US government unlawfully selected its medicines for the second round of the Medicare Drug Price Negotiation Program, dealing another loss for the pharmaceutical industry after other federal courts sided with the government program in several other similar cases.

“Teva’s claims either fail on the merits or are unripe,” Sooknanan said. “CMS’s definition of a qualifying single source drug is not arbitrary, capricious, or otherwise ...